Wednesday, November 30, 2022
HomeUnited Kingdom» Cellprothera starts new trials in MyPharma Editions in the UK

» Cellprothera starts new trials in MyPharma Editions in the UK

Published Friday, November 4, 2022

The French biotech Cellprothera is taking a new step in its development. In the UK, new centers join Edinburgh, Birmingham and Leeds. Centers as prestigious as St Bartholomew’s Hospital in London (Bart’s) and Ninewells Hospital in Dundee will take part in the heart regeneration clinical trial currently underway.

Professor Anthony Mathur, a pioneer of Anglo-Saxon stem cell research and professor emeritus at Queen Mary University of London, will become Principal Investigator across the Channel at London Bart’s.

Author of numerous publications on the treatment of cardiovascular disease and a pioneer in cell therapy targeting the heart, Professor Mathur has, among other things, established a compassionate care unit within Bart’s that uses stem cells to treat patients with heart failure.

“It gives me great pride to lead Cellprothera’s clinical trials in the UK. For years, my clinical work has focused on the care of patients for whom conventional treatment for heart failure has not worked. The solution developed by Cellprothera is promising and opens a new dimension in regenerative therapy” – Anthony Mathur

More information on Prof. Anthony Mathur’s career and publications: HERE

A new international partner

This new partnership illustrates the interest of Anglo-Saxon research in the solution developed by Cellprothera.

“We are very pleased to include these new leading centers in the treatment of cardiovascular disease in the UK in our trial. The participation of Prof. Anthony Mathur, an experienced cardiologist and pioneer in cell therapy and cardiac regeneration, is a great asset for the continuation of our clinical development.” – Mathieu de Kalbermatten, President of Cellprothera.

Source and visual: Cellprothera




Please enter your comment!
Please enter your name here

Most Popular

Recent Comments